Change of External Urethral Sphincter Function in Prostatic Patients

Yasuda, Kosaku; Nagashima, Kaoru; Murayama, Naoto; Yamanishi, Tomonori; Tojo, Masaki; Shimazaki, Jun

doi:10.1159/000282248

Cited by 8 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,4 Their method is characterized by the measurement of pressure at the maximum urinary flow rate (Qmax) at different levels of the urethra. Namely, their method measures 'cross-sectional' urinary parameters at Qmax or in the stable phase of urinary flow.…”

Section: Discussionmentioning

confidence: 99%

Non‐invasive estimation of intraurethral pressure profile from uroflowmetric curve

et al. 2004

View full text Add to dashboard Cite

Background : An intraurethral pressure-time profile as urodynamic information was obtained in a non-invasive manner using an equivalent equation as a voiding model. Methods : The reasonability of the voiding model was confirmed by applying it to an experimental flow curve likened to urinary flow. The flow curve was approximated and the pressure profile was estimated. From the uroflowmetric curves obtained in a normal subject and a patient with bladder outlet obstruction, the respective intraurethral pressure profiles were estimated. Results : The pressure profile estimated from the approximated flow curve was found consistent with the profile of the difference between the pressure actually measured at two different portions in the experimental system. Conclusion : Non-invasive estimation of intraurethral pressure profile from uroflowmetric curves may be very useful to grasp intraurethral urodynamic information in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Non‐invasive estimation of intraurethral pressure profile from uroflowmetric curve

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Anatomical obstruction of urethra caused by benign prostatic hyperplasia (BPH), functional obstruction of the urethra due to increased number of sympathetic a-adrenoceptors associated with BPH [ 11, and dysfunction of the urethral sphincter [2] have been reported to be responsible for voiding dysfunction in prostatic hyperplasia. It has been reported that a,-adrenoceptors exist predominantly in the tissue of prostatic adenoma and the prostatic capsule [3], sensibility to a,-blocker is higher in the tissue of BPH than in normal prostatic tissue [4], 40% of the total urethral pressure in BPH is due to a-adrenergic tone [51, and the dysfunction of the external urethral sphincter is recovered by a-blockers [2]. Since Caine et al [6] reported that phenoxybenzamine (POB), an a*-and a,-blocker, was effective in treating bladder outlet obstruction in BPH, there have been many reports of the usefulness of this drug in BPH patients.…”

Section: Introductionmentioning

confidence: 99%

Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies

et al. 1994

View full text Add to dashboard Cite

Thirty-two patients with voiding dysfunction attributable to symptomatic benign prostatic hyperplasia were treated with naftopidil, an alpha 1-blocker, at doses of 25-75 mg/day for 4-6 weeks. The efficacy of the drug was assessed from the changes in urinary symptoms and urodynamic data. Total symptom scores were significantly reduced after treatment (P < 0.001). Average flow rate and maximum flow rate were significantly increased (P < 0.001 and P < 0.001, respectively), and residual urine volume, residual urine rate (ratio of residual urine volume/sum of voided volume and residual urine volume), and maximum urethral closure pressure were significantly (P < 0.05, P < 0.01, and P < 0.05, respectively) reduced, and at bladder capacity, the first desire to void was significantly (P < 0.05) increased. The pressure/flow study demonstrated no changes in intravesical pressure at maximum flow, but a significant (P < 0.05) reduction in minimum urethral resistance. A mild side effect (dizziness) was noted in one patient (3.3%), which soon disappeared after the dose was decreased. The efficacy was good or excellent in 21 of 30 patients (70.0%). The drug was evaluated to be promising in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

show abstract